Controlling glycation of recombinant antibody in fed‐batch cell cultures
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Protein glycation is a non‐enzymatic glycosylation that can occur to proteins in the human body, and it is implicated in the pathogenesis of multiple chronic diseases. Glycation can also occur to recombinant antibodies during cell culture, which generates structural heterogeneity in the product. In a previous study, we discovered unusually high levels of glycation (>50%) in a recombinant monoclonal antibody (rhuMAb) produced by CHO cells. Prior to that discovery, we had not encountered such high levels of glycation in other in‐house therapeutic antibodies. Our goal here is to develop cell culture strategies to decrease rhuMAb glycation in a reliable, reproducible, and scalable manner. Because glycation is a post‐translational chemical reaction between a reducing sugar and a protein amine group, we hypothesized that lowering the concentration of glucose—the only source of reducing sugar in our fed‐batch cultures—would lower the extent of rhuMAb glycation. When we decreased the supply of glucose to bioreactors from bolus nutrient and glucose feeds, rhuMAb glycation decreased to below 20% at both 2‐L and 400‐L scales. When we maintained glucose concentrations at lower levels in bioreactors with continuous feeds, we could further decrease rhuMAb glycation levels to below 10%. These results show that we can control glycation of secreted proteins by controlling the glucose concentration in the cell culture. In addition, our data suggest that rhuMAb glycation occurring during the cell culture process may be approximated as a second‐order chemical reaction that is first order with respect to both glucose and non‐glycated rhuMAb. The basic principles of this glycation model should apply to other recombinant proteins secreted during cell culture. Biotechnol. Bioeng. 2011;108: 2600–2610. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reaction of Monosaccharides with Proteins: Possible Evolutionary Significance
Bunn, H. F., & Higgins, P. J. (1981) · Science · doi:10.1126/science.12192669 · Cited by 598
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Forced degradation of recombinant monoclonal antibodies: A practical guide
Nowak, C., K. Cheung, J., M. Dellatore, S., Katiyar, A., Bhat, R., Sun, J., Ponniah, G., Neill, A., Mason, B., Beck, A., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1368602 · Cited by 260
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
McAvan, B. S., Bowsher, L. A., Powell, T., O’Hara, J. F., Spitali, M., Goodacre, R., & Doig, A. J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00627 · Cited by 61
Kozma, B., Hirsch, E., Gergely, S., Párta, L., Pataki, H., & Salgó, A. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.06.070 · Cited by 41
Metadata
- Authors
- Yuk, I. H., Zhang, B., Yang, Y., Dutina, G., Leach, K. D., Vijayasankaran, N., Shen, A. Y., Andersen, D. C., Snedecor, B. R., & Joly, J. C.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2011-06-15
- Volume
- 108
- Issue
- 11
- Pages
- 2600-2610
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2168931684
- Cited by
- 79
- References
- 1
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlling glycation of recombinant antibody in fed‐batch cell cultures. https://app.cochat.ai/papers/10.1002/bit.23218
- The paper
- Yuk, I. H., Zhang, B., Yang, Y., Dutina, G., Leach, K. D., Vijayasankaran, N., Shen, A. Y., Andersen, D. C., Snedecor, B. R., & Joly, J. C. (2011). Controlling glycation of recombinant antibody in fed‐batch cell cultures. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.23218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.